Author name: Leonardo Arias

The planned purchase would allow Embecta to serve patients outside of diabetes care.

With the approval of Wegovy HD, Novo Nordisk joins Johnson & Johnson, Boehringer Ingelheim and USAntibiotics as beneficiaries of the FDA’s Commissioner’s National Priority Voucher program, which aims to review products that align with certain national priorities in less than two months.

The assets will add AI-backed care navigation capabilities to MedArrive’s home care logistics platform, so health systems can determine which patients are ready to transfer from acute care.

The head of the American Hospital Association attempted to defend consolidation. Members of a House Energy and Commerce subcommittee were unmoved.

Sarepta Therapeutics says the FDA has agreed to review a regulatory package for Amondys 45 and Vyondys 53 after they failed a confirmatory trial, but whether the agency will agree to approve them is still unknown.

The company is establishing commercial production capabilities to fuel plans to launch autologous CAR-T cell therapies in China.

Eli Lilly’s retatrutide could present a “differentiated option” for patients with type 2 diabetes who want to control their blood sugar and achieve maximal weight loss, according to analysts at BMO Capital Markets.

Prime biotech buyout targets such as Revolution Medicines and BioCryst Pharmaceuticals have recently found themselves in the middle of acquisition rumors—though no deals have panned out so far.

Gossamer Bio reported last month that its only late-stage candidate failed a Phase 3 study in pulmonary arterial hypertension, casting doubt on the asset’s future prospects.

Hay enfermedades que guardan sus secretos con una obstinación inesperadamente férrea. La epilepsia es una de ellas. Una minirrevisión de resultados de estudios, publicada recientemente en la revista académica Genomic Psychiatry, sintetiza el panorama en rápida expa …